Chiome Bioscience Inc.
Research Chiome Bioscience Inc. (4583.T) on Bullrun: market cap JPY 7.30B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4583.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 7.30B
- Financial periodFY2025
- RevenueJPY 593.29M
- Revenue growth-24.0%
- Net income-JPY 982.78M
- Free cash flow-JPY 976.07M
- Gross margin59.9%
Valuation Snapshot
latest market cap is JPY 7.30B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 593.29M | -JPY 982.78M | -JPY 976.07M | 59.9% | -17.54 | JPY 1.21B | JPY 261.70M | JPY 1.12B |
| FY2024 | JPY 780.81M | -JPY 1.02B | -JPY 1.00B | 55.4% | -17.54 | JPY 2.06B | JPY 281.50M | JPY 1.92B |
| FY2023 | JPY 682.46M | -JPY 1.22B | -JPY 1.07B | 58.4% | -24.62 | JPY 1.33B | JPY 291.00M | JPY 1.16B |
| FY2022 | JPY 630.82M | -JPY 1.24B | -JPY 1.19B | 55.3% | -28.26 | JPY 1.73B | JPY 184.00M | JPY 1.79B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 7.30B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Chiome Bioscience Inc.
Chiome Bioscience Inc. engages in the research and development of antibody drugs in Japan, Singapore, and internationally. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib system, a monoclonal antibody production technology that uses chicken immune cells to produce antibodies for drug discovery research. It also develops drugs under Phase I clinical trial, including ADCT-701, a humanized anti-dlk1 antibody for the treatment of solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Chiome Bioscience Inc.'s market cap?
Chiome Bioscience Inc.'s market capitalization is JPY 7.30B.
What does Chiome Bioscience Inc. do?
Chiome Bioscience Inc. engages in the research and development of antibody drugs in Japan, Singapore, and internationally. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib system, a monoclonal antibody production technology that uses chicken immune cells to produce antibodies for drug discovery research.